-transparent.png){kind=logo}
Plasma and spinal fluid levels of complement activation products C3a and C5a were quantitated by radioimmunoassay in a group of 16 patients suffering from acute monophasic Guillain-Barré syndrome (GBS). Median CSF levels of C3a (118 ng/ml) and of C5a (9.6 ng/ml) were significantly elevated when compared with samples from a control group of patients with noninflammatory neurologic diseases. Plasma concentrations of these anaphylotoxic peptides were not significantly different between the two populations. Our findings indicate that the complement system is activated in the CSF of patients with acute GBS. Complement activation products may contribute to the inflammatory changes observed in this disorder.
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
February 2006,
Proceedings of the National Academy of Sciences of the United States of America,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
December 1982,
Lancet (London, England),
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
June 1986,
Journal of immunology (Baltimore, Md. : 1950),
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
June 2019,
Brain and nerve = Shinkei kenkyu no shinpo,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
January 1988,
Methods in enzymology,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
December 1977,
Neurology,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
June 2008,
Nihon rinsho. Japanese journal of clinical medicine,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
February 2010,
Pain,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
November 1987,
The Journal of clinical investigation,
H P Hartung, and
C Schwenke, and
D Bitter-Suermann, and
K V Toyka
April 1987,
Acta neurologica Scandinavica,
